The Korean Journal of Medicine

  • 제87권4호
  • /
  • Pages.496-500
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Azacitidine 치료 후 폐 손상이 발생한 골수형성이상증후군 1예

Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome

  • 김호철 (울산대학교 의과대학 내과학교실) ;
  • 김상형 (울산대학교 의과대학 내과학교실) ;
  • 안지환 (울산대학교 의과대학 내과학교실) ;
  • 권혜미 (울산대학교 의과대학 내과학교실) ;
  • 최종한 (울산대학교 의과대학 내과학교실) ;
  • 김태형 (울산대학교 의과대학 내과학교실) ;
  • 이제환 (울산대학교 의과대학 내과학교실)
  • Kim, Ho Cheol (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Kim, Sang Hyung (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Ahn, Jee Hwan (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Kwon, Hye Mi (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Choi, Jong Han (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Kim, Tae Hyung (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Lee, Je-Hwan (Department of Internal Medicine, University of Ulsan College of Medicine)
  • 투고 : 2013.11.03
  • 심사 : 2014.01.09
  • 발행 : 2014.10.01
⟨ 이전 논문 다음 논문 ⟩

초록

저자들은 골수형성이상증후군 환자에서 azacitidine 치료 시행 후에 발생한 폐 손상을 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78-year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient's subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.

키워드

참고문헌

  1. Choi CW. The NCCN clinical practice guidelines and best supportive care for the myelodysplastic syndromes. Korean J Med 2009;76:137-142.
  2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232. https://doi.org/10.1016/S1470-2045(09)70003-8
  3. Adams CD, Szumita PM, Baroletti SA, Lilly CM. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Pharmacotherapy 2005;25:765-768. https://doi.org/10.1592/phco.25.5.765.63579
  4. Hueser CN, Patel AJ. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. Pharmacotherapy 2007;27:1759-1762. https://doi.org/10.1592/phco.27.12.1759
  5. Sekhri A, Palaniswamy C, Kurmayagari K, Kalra A, Selvaraj DR. Interstitial lung disease associated with azacitidine use: a case report. Am J Ther 2012;19:e98-100. https://doi.org/10.1097/MJT.0b013e3181e7a526
  6. Nair GB, Charles M, Ogden L, Spiegler P. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome. Respir Care 2012;57:631-633. https://doi.org/10.4187/respcare.01338
  7. Pillai AR, Sadik W, Jones PA, Thachil J. Interstitial pneumonitis: an important differential diagnosis for pulmonary sepsis in haematology patients. Leuk Res 2012;36:e39-40. https://doi.org/10.1016/j.leukres.2011.09.024
  8. Hayashi M, Takayasu H, Tada M, et al. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan. Intern Med 2012;51:2411-2415. https://doi.org/10.2169/internalmedicine.51.8167
  9. Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009;35:1526-1531. https://doi.org/10.1007/s00134-009-1482-8
  10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245. https://doi.org/10.1038/clpt.1981.154